Breaking News

Cytovance Manufactures ARMO’s Lead Candidate

Provides drug product for Phase I trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cytovance Biologics has completed GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10) being studied in advanced solid tumors.   “Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters